Medicenna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018
Net Income	-10.05	-22.58	-17.29	-8.28	-4.71
Depreciation & Amortization	0	0.04	0.04	0.01	0.01
Share-Based Compensation	1.37	1.42	1.01	1.13	1
Other Operating Activities	-3.98	-2.46	0.93	1.73	-4.33
Operating Cash Flow	-12.66	-23.58	-15.31	-5.42	-8.04
Capital Expenditures	0	0	0	0	-0.35
Change in Investments	0	10.05	5.01	-15	0
Investing Cash Flow	0	10.05	5.01	-15	-0.35
Share Issuance / Repurchase	24.76	3.92	18.3	40.75	3.58
Debt Issued / Paid	0	-0.04	-0.04	-0	0
Other Financing Activities	-	-	-	-	3.24
Financing Cash Flow	24.76	3.88	18.26	40.75	6.82
Exchange Rate Effect	0.96	-0.18	-0.28	-0	0.03
Net Cash Flow	13.06	-9.84	7.68	20.33	-1.57
Free Cash Flow	-12.66	-23.58	-15.31	-5.42	-8.39
Free Cash Flow Per Share	-0.20	-0.43	-0.31	-0.17	-0.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).